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A comparative clinical study between Ensure and Elental was tried to evaluate clinical 
usefulness and side effects in postoperative nutrition of patients received esophago-gastric surgery. 
The patients were divided by random sampling and no significant difference was observed in 
background such as age, sex, diseases, operat10n performed and calories administered between 
the two groups. 
The increase of serum albumin value was significantly more in the Ensure group than in the 
Elental group, while serum uric acid was elevated in the latter group much more than in the 
former. These results suggested that the administered proteins of Ensure were more effectively 
used in the body than amino acids of Elental. Significant elevation of serum triglyceride in the 
Elental group indicated abnormal lipid metabolism probably because of minimum content of 
lipid in Elental. Moreover, linoleic acid was significantly elevated in the Ensure group and 
decreased in the Elental group. Although C20 : 3/C20 : 4 ratio, the ordinary index of essential 
fatty acid (EFA) status, remained at the same level in the both groups, al cases in the Ensure 
group showed a decrease in thew 9/w 6 ratio, a new parameter evaluating EFA status proposed 
by us, whereas al cases in the Elental group showed an increase in the ratio. Therefore, Ensure 
is preferable to Elental with respect to prevention and treatment of EFA deficiency. No 
statistically significant differences between the two groups were noted in other parameters includ-
ing body weight, mid-arm circumference, nitrogen balance and fasting blood sugar level. 
Side effects mainly diarrhea were observed in 30.0% of cases in the Ensure group and in 
57.7% in the Elental group, but no statistical significance was obtained. Either nutritional 
status or facilities assessed by each surgeon was similar in the both groups. Utility of these 
drugs was evaluated with the score of the side effects, nutritional status and facilities. In the 
Ensure group 90.0% of cases were evaluated to be useful, while 76.9% in the Elental group. 
From these results it might be concluded that Ensure can be administered as an ente:.-al diet to 



































エンシュアは250kcaJ/237 ml ( 1缶）のリキッドタ
イプのものを用い．エレンタールは市販の 300kcal/




















蛋白質 I3. 52 g I 4石i
脂肪 I3. 52 g I o. os g 
炭水化物 I13. 1 I 2i.口
ビタミン A I 250 lU I 216 IU 
ビタミン D 20 lU 17. 3 IU 
ピ ビタミン E 3 mg 1.1 mg 
ビタミ y K 14 ,.g 2.9 μg 
タ ビタミン C 15. 2 mg 2.6 mg 
ビタミン B1 152 ,.g 51 ,.g 
ビタミン B2 172 ,.g 81 μg 、
ビタミン Bs 200 73 ,.g ,.g 
ビタミン B12 o. 6,.g 0. 23μg 
ン コ ン 52 mg 2.9 mg 
業 酸 20 ,.g 15' μg 
0.5 mg 0.4 mg 
ナイアシン 2 mg O. 7 mg 
ピオチン 15. 2 ,.g I 13 μg 
ナトリウム 80 mg 87 mg 
、 カ ウ ム 148 mg 73 mg 
塩 素 136 mg 172 mg 
カ Jレシウム 52 mg 53 mg 
耳、
ン 52 mg 41 mg 
マグネシウム 20 mg 13 mg 
フ ョーF ソ t ン 0.2 mg 0.1 mg 
銅 0.1 mg 0.07mg 
Jレ 亜 鉛 0.6 mg 
鉄 0.9 mg 0.6 mg 
＊アミノ酸として含有


















ゼ， GOT,GPT, y-GTP, LDH, AI-P，総ビリルヒ。














～ 3 0才 。 。
3 1 ～ 4 0才 1 2 
4 1 ～ 5 0才 1 。
5 1 ～ 6 0才 3 2 
6 1 ～ 7 0才 4 1 

























。 。 。 。
。 。 。 3 
1 3 4 5 
3 5 8 13 
6 7 13 18 
。 1 1 7 




疾患名｜ エンシ A ア エレンタ －）レ
胃 癌 15 ( 75.0%) 19 ( 73.1%) 
食 道 癌 2 ( 10. 0%) 4 ( 15.4%) 
胃 潰 場 2 ( 10. 0%) 1 ( 3. 87ぢ）
十二脂腸潰蕩 1 ( 5. 07ぢ） 1 ( 3. 8%) 
食道潰場 。（ 0 %) 1 ( 3. 85ぢ）
計 20 (lo. 05ぢ） 26 (lo. O%) 
検定 NS (X2検定〉
計
34 ( 73. 9%) 
6 ( 13.0%) 
3 ( 6. 57ぢ）
2 ( 4.3%) 
1 ( 2.2%) 
46 (lo. 0%) 
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表4. 手術術式
術 式 エンシ A ア
胃 全 摘 9 ( 45.0，$初
胃 切 除 9 ( 45.0%) 
食道癌根治術 2 ( 10. 0%〕
食道再建 0 ( 0 %) 



















14 ( 53.8%) 23 ( 50.0%) 
7 ( 26. 9%) 16 ( 34. 8.$紛
4 ( 15. 4，$ぢ） 6 ( 13.0%) 
1 ( 3.8%) 1 ( 2. 2形）








































6 ( 30.0第） 9 ( 34. 6%) 
8 ( 40.0%) 7 ( 26.9%) 
4 ( 20.0忽） 9 ( 34.6，$紛
2 ( 10. 0%) 1 ( 3.8%) 
20 (100. 0%) 26 (100.0忽）
計
37 ( 80. 4%) 
9 ( 19. 6第）
46 (100. 0%) 
計
15 ( 32.筋）
15 ( 32. 6，$ぢ）
13 ( 28. 3%) 
3 ( 6. 5，$ぢ）




投与量（kcal/日） エンシ」ア エレンタ －）レ 計
1.000未満 0 ( 0 ~ぢ） 1 ( 3.8~ぢ〉 1 ( 2.2%) 
1.000以上 1.500未満 7 ( 35. 0彪） 7 ( 26.9%) 14 ( 30. 496) 
1.500以上 2.000未満 11 ( 55.0%) 17 ( 65. 4%) 28 ( 60.9%) 
2.000以上 2 ( 10. 0%) 1 ( 3.87ぢ） 3 ( 6.5%) 
計 20 (100.0%) 26 (100.0$ぢ） 46 (100.0%) 
検定 NS(U検定）
表8. 投与日数
投与日数 エンシ ι ア
1 3日 0 ( 0 %) 
4 7日 12 ( 60.0%) 
8 14日 8 ( 40. 0$初



























1 ( 3.8$初 1 ( 2.2%) 
8 ( 30. 8$ぢ） 20 ( 43.5%) 
15 ( 57. 7$初 23 ( 50.0%) 
2 ( 7.7$初 2 ( 4. 35ぢ）
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1. 8土1.4 -o. 4士1.2 
34.8土3.9 -0.7土3.8
































































































1. 2±0. 7 
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《n= 7、 < n = 7) 
b・fore alter bet。，． eft・r
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0 ( 0 %) 
17 ( 85. 0%) 
3 ( 15. 0%) 

















11 ( 42. 3%) 
9 ( 34.6%) 
2 ( 7.8%) 
4 ( 15. 4~ぢ）
26 (lo. 0%) 
表13. 総合判定（有用性）
I エンシュァ ｜ 
10 c so.0%) I 
8 ( 40.0%) ! 
1 c s.0%) I 
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